Skip to content
Screener

Bicara Therapeutics BCAX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Eli Lilly logo
Eli LillyLLY
$142.28B+41.0%
Amgen logo
AmgenAMGN
$95.64B+8.8%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$349.3M+62.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$924M-14.0%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$183.97M-24.2%
Immunome logo
ImmunomeIMNM
$619.79M+80.9%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.81B+217%
Enterprise value$1.49B+1,000%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033429
Line itemMarch 31, 2026December 31, 2025
Stockholders' equity:
Preferred stock $0.0001 par value, 10,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, $0.0001 par value, 500,000,000 and 500,000,000 shares authorized; 65,547,037 and 56,600,724 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively87
Additional paid-in capital929,370760,168
Accumulated other comprehensive (loss) income(243)243
Accumulated deficit(415,177)(358,966)
Total stockholders' equity513,958401,452
Total liabilities and stockholders’ equity$553,599$430,994

Item 1. Financial Statements (Unaudited)

FAQ

What is Bicara Therapeutics's total liabilities & equity?
Bicara Therapeutics (BCAX) reported total liabilities & equity of $553.6M in Q1 2026.
How has Bicara Therapeutics's total liabilities & equity changed year-over-year?
Bicara Therapeutics's total liabilities & equity increased by 15.8% year-over-year, from $478.08M to $553.6M.
What is the long-term trend for Bicara Therapeutics's total liabilities & equity?
Over 2 years (2023 to 2025), Bicara Therapeutics's total liabilities & equity has grown at a 35.7% compound annual growth rate (CAGR), from $233.98M to $430.99M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Bicara Therapeutics's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude